Rare liver diseases are challenging indications in clinical development. Conditions such as primary biliary cholangitis, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis, and Alagille syndrome are defined by low patient prevalence, complex disease biology, and a profound unmet need. The affected populations are small, geographically dispersed, and frequently underserved, requiring a level of operational sophistication and scientific depth that conventional development paradigms are ill-equipped to support. These trials require advanced diagnostics and expertise to accurately incorporate them and obtain meaningful data. Moreover, regulatory expectations introduce added complexity. Orphan drug designations, accelerated approval pathways, pediatric strategic considerations, and multi-jurisdictional pre-submission engagement with multiple global regulatory bodies demand strategic precision and deep institutional knowledge.
Read our fact sheet to learn more about our rare liver disease expertise and how it can help advance your rare liver studies.
